June 06, 2026 05:46 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
After Annamalai exit, BJP gives up Andhra Rajya Sabha seat in NDA rejig | K. Annamalai quits BJP, triggers speculations over his new party | RBI hits pause button again! Repo rate remains unchanged at 5.25% amid global turmoil | 'Was it directed by ruling ecosystem?': Congress questions LIC stake in Rajesh Exports under SEBI scanner | Boost for Congress! Vijay allots Tamil Nadu's lone Rajya Sabha seat to key ally | Fresh trouble for Mamata: Complaint filed over explosive Amit Shah claim in Osman Hadi case | 'Communication gap': Rajesh Exports rejects SEBI allegations, says revenues were not overstated | ₹15.2 lakh crore revenue questioned! SEBI action sends Rajesh Exports shares tumbling | 'If not now, when!': Sonam Wangchuk backs Cockroach Janta Party protest; spokespersons named ahead of founder Abhijeet Dipke's India return | Cabinet approves Rs. 10,000 crore support package to stabilise ATF prices for airlines
Pregnancy
Pixabay

U.S. FDA approves first nonprescription daily oral contraceptive

| @indiablooms | Jul 14, 2023, at 03:30 pm

Los Angeles: The U.S. Food and Drug Administration (FDA) on Thursday approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy, which is the first daily oral contraceptive approved for use in the United States without a prescription.

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider, said the FDA in a statement.

The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA.

"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.